172
Participants
Start Date
February 17, 2025
Primary Completion Date
April 30, 2028
Study Completion Date
June 30, 2028
Infliximab
Infliximab 5 mg/kg i.v at Weeks 0, 2, 6 and then every 8 weeks for 52 weeks.
Ustekinumab
Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks.
RECRUITING
Oddział Kliniczny Gastroenterologii Ogólnej i Onkologicznej USK nr 1 im. N. Barlickiego w Łodzi, Lodz
Collaborators (1)
Poznan University of Medical Sciences
OTHER
Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań
OTHER
Norbert Barlicki Memorial Teaching Hospital No. 1 of the Medical University of Lodz
UNKNOWN
Medical Research Agency, Poland
OTHER_GOV
Medical University of Lodz
OTHER